AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $46.38.

Several analysts have recently commented on the company. Stifel Nicolaus assumed coverage on AnaptysBio in a research note on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of AnaptysBio in a report on Friday, May 10th. JPMorgan Chase & Co. reduced their target price on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, April 1st. SVB Leerink began coverage on AnaptysBio in a report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dennis Mulroy sold 1,500 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total value of $35,580.00. Following the completion of the transaction, the chief financial officer now directly owns 964 shares of the company’s stock, valued at $22,866.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 152,390 shares of company stock valued at $3,469,515. Company insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently made changes to their positions in the stock. First Light Asset Management LLC boosted its holdings in shares of AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the period. Great Point Partners LLC raised its position in shares of AnaptysBio by 9.2% in the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after buying an additional 82,648 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in shares of AnaptysBio in the third quarter worth $7,669,000. Franklin Resources Inc. raised its position in shares of AnaptysBio by 22.7% in the fourth quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after buying an additional 75,025 shares in the last quarter. Finally, StemPoint Capital LP raised its position in shares of AnaptysBio by 499.0% in the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after buying an additional 224,548 shares in the last quarter.

AnaptysBio Stock Performance

ANAB stock opened at $22.89 on Thursday. The stock’s 50 day simple moving average is $23.50 and its 200 day simple moving average is $22.79. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $27.50. The company has a market cap of $625.35 million, a P/E ratio of -3.73 and a beta of -0.33.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.10). AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. The firm had revenue of $7.18 million for the quarter, compared to analyst estimates of $4.55 million. Equities analysts predict that AnaptysBio will post -6.04 earnings per share for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.